8 Trillion Won IBD New Drug Stock Adjusts 1.8% After Clinical News

On April 12, Spyre Therapeutics Inc. (NASDAQ: SYRE) closed at $75.04, down 1.82% on the Nasdaq.

Trading volume reached approximately 1.23 million shares, above its recent average, and market capitalization declined by about $116 million (roughly ₩150 billion) in a single day, bringing total market value to around $6.5 billion (about ₩8.5 trillion).

On April 13, the company reported that its lead candidate, SPY001, met the primary endpoint and demonstrated meaningful efficacy—including a 40% clinical remission rate—and excellent tolerability in Part A of the Phase 2 SKYLINE trial in patients with moderate-to-severe ulcerative colitis, bolstering expectations for a new IBD therapy.

In its recently released Q4 2025 financial report, Spyre highlighted cash and marketable securities of $756 million (approximately ₩1 trillion) and a cash runway extending into the second half of 2028, underscoring its financial capacity to support further clinical development.

Spyre Therapeutics is a clinical-stage biotech company developing long-acting antibodies targeting α4β7, TL1A, and IL-23—and combination regimens—for the treatment of inflammatory bowel disease and rheumatic conditions.

The company is testing multiple candidates in parallel in its SKYLINE and SKYWAY Phase 2 platform trials, with additional interim and top-line data expected between 2026 and 2027, making the stock potentially highly volatile based on clinical outcomes.